John Pare, DO
Family Medicine · Millville, DENPI 1952395451
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,499 and has fallen 74.6% since, to $381 in 2024.
Across 207 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$677
- AstraZeneca$643
- Lilly USA, LLC$530
- AbbVie$422
- Boehringer Ingelheim$405
- GSK$310
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,771100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $677 |
| AstraZeneca | 19 | $643 |
| Lilly USA, LLC | 28 | $530 |
| AbbVie(2 entities) | 18 | $422 |
| Boehringer Ingelheim | 29 | $405 |
| GSK | 9 | $310 |
| Amgen | 12 | $277 |
| E.r. Squibb & Sons, L.L.C. | 3 | $265 |
| Cardiovascular Systems Inc. | 2 | $195 |
| Amarin Pharma, Inc. | 9 | $164 |
| Pfizer | 8 | $125 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $125 |
| Exact Sciences | 5 | $92 |
| Idorsia Pharmaceuticals US Inc | 3 | $67 |
| Astellas Pharma US Inc | 4 | $65 |
| Abbott | 3 | $59 |
| Eisai Inc. | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Vanda Pharmaceuticals Inc. | 3 | $51 |
| Bayer | 3 | $46 |
| Merck | 2 | $27 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
| Vertos Medical, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Dermira, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$254
- NURTEC ODT$125
- AREXVY$119
- BREZTRI AEROSPHERE$114
- Diamondback Coronary$109
How this compares
$4,771 in reported general payments places this provider in the 85th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 86 | $126,769 |
| JardianceEmpagliflozin | 56 | $78,671 |
| OzempicSemaglutide | 43 | $65,518 |
| TrulicityDulaglutide | 21 | $47,371 |
| XareltoRivaroxaban | 24 | $27,084 |
| MyrbetriqMirabegron | 19 | $24,761 |
| MounjaroTirzepatide | 23 | $23,810 |
| JanuviaSitagliptin Phosphate | 13 | $21,087 |
| FarxigaDapagliflozin Propanediol | 12 | $18,238 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $13,037 |
| Atorvastatin Calcium | 799 | $7,421 |
| VascepaIcosapent Ethyl | 12 | $6,644 |
| Levothyroxine Sodium | 345 | $5,255 |
| Rosuvastatin Calcium | 321 | $4,775 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $125 | $128,137106 claims |
| Boehringer IngelheimJardiance | $405 | $78,67156 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $530 | $71,18244 claims |
| Novo NordiskOzempic | $677 | $65,51843 claims |
| Astellas Pharma US IncMyrbetriq | $65 | $24,76119 claims |
| AstraZenecaFarxiga, Symbicort | $643 | $22,68925 claims |
| MerckJanuvia | $27 | $21,08713 claims |
| GSKBreo Ellipta | $310 | $13,03715 claims |
| AbbVieSynthroid | $422 | $3,65981 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 352 family medicine providers in Delaware.
Other family medicine in Millville
- Gregory PapaNew Castle$67K
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- Michelle PapaNewark$23K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
- Wayne TuckerBear$20K
- Ian MyersNewark$17K
- Glenn HamiltonWilmington$17K
- Dustin DavisGeorgetown$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.